Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Female Sexual Dysfunction Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Female Sexual Dysfunction Overview | 9 | 1 |
| Pipeline Products for Female Sexual Dysfunction Comparative Analysis | 10 | 1 |
| Female Sexual Dysfunction Therapeutics under Development by Companies | 11 | 1 |
| Female Sexual Dysfunction Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Female Sexual Dysfunction Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Female Sexual Dysfunction Products under Development by Companies | 16 | 1 |
| Female Sexual Dysfunction Products under Investigation by Universities/Institutes | 17 | 1 |
| Female Sexual Dysfunction Companies Involved in Therapeutics Development | 18 | 8 |
| Apricus Biosciences, Inc. | 18 | 1 |
| Emotional Brain BV | 19 | 1 |
| EndoCeutics, Inc. | 20 | 1 |
| M et P Pharma AG | 21 | 1 |
| Palatin Technologies, Inc. | 22 | 1 |
| Re-Pharm Limited | 23 | 1 |
| TherapeuticsMD, Inc. | 24 | 1 |
| Valeant Pharmaceuticals International, Inc. | 25 | 1 |
| Female Sexual Dysfunction Therapeutics Assessment | 26 | 10 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Combination Products | 27 | 1 |
| Assessment by Target | 28 | 2 |
| Assessment by Mechanism of Action | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 31 |
| (sildenafil citrate + testosterone) Drug Profile | 36 | 2 |
| alprostadil Drug Profile | 38 | 7 |
| bremelanotide Drug Profile | 45 | 5 |
| prasterone Drug Profile | 50 | 2 |
| S1B-3006 Drug Profile | 52 | 1 |
| S1B-307 Drug Profile | 53 | 1 |
| SIP-104 Drug Profile | 54 | 2 |
| Small Molecule for Sexual Dysfunction Drug Profile | 56 | 1 |
| Small Molecules to Agonize Dopamine for Sexual Dysfunction Drug Profile | 57 | 1 |
| SPT-201 Drug Profile | 58 | 1 |
| Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction Drug Profile | 59 | 1 |
| TBS-2 Drug Profile | 60 | 4 |
| TX-004HR Drug Profile | 64 | 3 |
| Female Sexual Dysfunction Dormant Projects | 67 | 3 |
| Female Sexual Dysfunction Discontinued Products | 70 | 1 |
| Female Sexual Dysfunction Product Development Milestones | 71 | 9 |
| Featured News &Press Releases | 71 | 1 |
| May 14, 2016: TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial | 71 | 1 |
| Mar 02, 2016: TherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor &Medical Conferences | 71 | 1 |
| Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting | 72 | 1 |
| Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women s Sexual Health Annual Meeting | 72 | 1 |
| Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction | 73 | 1 |
| Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause | 73 | 1 |
| Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction | 74 | 1 |
| Dec 07, 2015: TherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR | 75 | 1 |
| Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference | 76 | 1 |
| Sep 09, 2015: TherapeuticsMD Announces Presentations at The North American Menopause Society 2015 Annual Meeting | 76 | 1 |
| Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder | 76 | 1 |
| Aug 19, 2015: Apricus Biosciences Announces it is Seeking a Global Partner for Femprox, a Novel Treatment for Female Sexual Dysfunction | 77 | 1 |
| Aug 18, 2015: Palatin Technologies Supports FDA's Approval of the First-Ever Treatment for Female Sexual Dysfunction | 78 | 1 |
| Jun 11, 2015: Trimel Confirms Next FDA Meeting on TEFINA | 79 | 1 |
| Jun 09, 2015: TherapeuticsMD Completes Enrollment in The Rejoice Trial, a Phase 3 Clinical Trial of TX-004HR | 79 | 1 |
| Appendix | 80 | 2 |
| Methodology | 80 | 1 |
| Coverage | 80 | 1 |
| Secondary Research | 80 | 1 |
| Primary Research | 80 | 1 |
| Expert Panel Validation | 80 | 1 |
| Contact Us | 80 | 1 |
| Disclaimer | 81 | 1 |